ATP13A2/PARK9 Lysosomal Function Therapies for Parkinson's Disease

ATP13A2/PARK9 Lysosomal Function Therapies for Parkinson's Disease

Overview

| Attribute | Value |
|-----------|-------|
| Category | Disease-Modifying Therapy |
| Target | ATP13A2/PARK9 lysosomal P5-ATPase |
| Diseases | Parkinson's Disease, Kufor-Rakeb Syndrome, Atypical Parkinsonism |
| Development Stage | Preclinical |
| Mechanism | Lysosomal calcium homeostasis, metal ion transport, autophagy regulation |

Introduction

[ATP13A2](/genes/atp13a2) (also known as [PARK9](/genes/atp13a2)) encodes a lysosomal P5-type ATPase that is critical for lysosomal function and neuronal survival. Loss-of-function mutations in [ATP13A2](/genes/atp13a2) cause Kufor-Rakeb syndrome (KRS), a rare autosomal recessive disorder characterized by [Parkinsonism](/diseases/parkinsons-disease), cognitive decline, and pyramidal tract involvement. [@ramirez2006]

Interestingly, common [ATP13A2](/genes/atp13a2) variants modify [Parkinson's disease](/diseases/parkinsons-disease) risk, and ATP13A2 expression is reduced in sporadic PD brains. This suggests that enhancing ATP13A2 function could have therapeutic benefit beyond rare genetic forms. [@chen2022]

ATP13A2 Biology

Protein Structure

ATP13A2 is a large transmembrane protein with:

• P5-ATPase core: Catalytic domain for ion transport [@schultheis2004]
• Lysosomal targeting sequence: Directs protein to lysosome [@kettner2021]
• Multiple transmembrane domains: Spans lysosomal membrane [@sousa2019]

Normal Function

...

ATP13A2/PARK9 Lysosomal Function Therapies for Parkinson's Disease

Overview

| Attribute | Value |
|-----------|-------|
| Category | Disease-Modifying Therapy |
| Target | ATP13A2/PARK9 lysosomal P5-ATPase |
| Diseases | Parkinson's Disease, Kufor-Rakeb Syndrome, Atypical Parkinsonism |
| Development Stage | Preclinical |
| Mechanism | Lysosomal calcium homeostasis, metal ion transport, autophagy regulation |

Introduction

[ATP13A2](/genes/atp13a2) (also known as [PARK9](/genes/atp13a2)) encodes a lysosomal P5-type ATPase that is critical for lysosomal function and neuronal survival. Loss-of-function mutations in [ATP13A2](/genes/atp13a2) cause Kufor-Rakeb syndrome (KRS), a rare autosomal recessive disorder characterized by [Parkinsonism](/diseases/parkinsons-disease), cognitive decline, and pyramidal tract involvement. [@ramirez2006]

Interestingly, common [ATP13A2](/genes/atp13a2) variants modify [Parkinson's disease](/diseases/parkinsons-disease) risk, and ATP13A2 expression is reduced in sporadic PD brains. This suggests that enhancing ATP13A2 function could have therapeutic benefit beyond rare genetic forms. [@chen2022]

ATP13A2 Biology

Protein Structure

ATP13A2 is a large transmembrane protein with:

• P5-ATPase core: Catalytic domain for ion transport [@schultheis2004]
• Lysosomal targeting sequence: Directs protein to lysosome [@kettner2021]
• Multiple transmembrane domains: Spans lysosomal membrane [@sousa2019]

Normal Function

Pathogenic Mechanisms

Lysosomal Dysfunction

ATP13A2 deficiency causes:

• Impaired lysosomal calcium buffering [@tsunemi2014]
• Metal ion homeostasis disruption [@vanveen2019]
• Reduced autophagic flux [@usenko2020]
• Enhanced [alpha-synuclein](/proteins/alpha-synuclein) accumulation [@podhajska2012]

Metal Ion Dysregulation

The lysosome is a critical node for [metal ion](/mechanisms/metal-ion-homeostasis-parkinsons) homeostasis:

• Manganese: Accumulation causes oxidative stress [@schneider2020]
• Zinc: Disrupted signaling affects autophagy [@fei2024]
• Calcium: Impaired buffering affects [autophagy](/mechanisms/autophagy-lysosomal-pathway-parkinsons) regulation [@bussian2018]

Relationship to Alpha-Synuclein

ATP13A2 dysfunction promotes [alpha-synuclein pathology](/mechanisms/alpha-synuclein-aggregation-pathway): [@usenko2021]

• Lysosomal impairment reduces alpha-synuclein clearance [@bose2018]
• Metal dysregulation promotes aggregation [@chen2022]
• Autophagic blockade allows toxic species to accumulate [@tsunemi2014]

Therapeutic Strategies

Gene Therapy

| Vector | Target | Delivery | Status |
|--------|--------|----------|--------|
| AAV2/9-ATP13A2 | CNS neurons | Intraparenchymal | Preclinical |
| AAV-PARK9 | Dopaminergic neurons | Stereotactic | Research |
| Lentivirus-ATP13A2 | Broad CNS | IV infusion | Discovery |

Gene therapy approaches using AAV vectors have shown promise in preclinical models. [@chen2024]

Small Molecule Approaches

| Strategy | Compound Class | Mechanism | Development Stage |
|----------|---------------|-----------|-------------------|
| Lysosomal function enhancers | TFEB activators | Increase lysosomal biogenesis | Preclinical |
| Autophagy inducers | mTOR inhibitors | Enhance autophagic flux | Phase I-II |
| Metal chelators | EDTA analogs | Reduce Mn/Zn overload | Preclinical |
| Calcium modulators | L-type blockers | Restore lysosomal Ca²⁺ | Research |

Small molecule activators of ATP13A2 function are being developed for potential therapeutic use. [@gomes2024]

Mechanism-Specific Treatments

Calcium modulators: Restore lysosomal calcium handling — Store-operated calcium entry (SOCE) modulators under investigation

Metal ion stabilizers: Normalize ion homeostasis — DMT1 inhibitors and ferroportin agonists

TFEB activators: Enhance lysosomal biogenesis — GBA agonists and mTOR-independent activators

Autophagy enhancers: Trehalose, rapamycin, and novel small molecules bypass ATP13A2 dysfunction

Clinical Pipeline

| Agent | Company | Mechanism | Trial Phase |
|-------|---------|-----------|-------------|
| AAV-ATP13A2 | NeuRon/Prevail | Gene replacement | Preclinical |
| ATL-02 | Appvian | TFEB activator | Preclinical |
| Genistein | Natural product | Autophagy induction | Research |

Preclinical Evidence

Animal Models

| Model | Phenotype | Therapeutic Response |
|-------|-----------|---------------------|
| ATP13A2 KO mice | Progressive neurodegeneration, motor deficits | AAV-ATP13A2 rescue |
| KRS patient iPSC neurons | Lysosomal dysfunction, α-syn accumulation | Gene therapy |
| Zebrafish atp13a2 morphants | Developmental deficits, locomotor defects | Metal chelation |

• ATP13A2 knockout mice show progressive neurodegeneration [@sato2018]
• AAV-ATP13A2 delivery protects dopaminergic neurons [@ferris2020]
• Metal chelation improves phenotype in models [@tanaka2020]
• TFEB activation enhances lysosomal biogenesis [@zhang2021]

In Vitro Studies

• Cell models: ATP13A2 knockdown in SH-SY5Y cells recapitulates PD phenotypes
• iPSC-derived neurons: Patient neurons show impaired lysosomal calcium handling [@tanaka2024]
• Metal studies: Manganese accumulation exacerbates oxidative stress [@bollimunka2021]

Mechanism Validation

• ATP13A2 restoration reduces alpha-synuclein pathology
• Improves lysosomal function markers
• Enhances motor function in models
• Restores proper autophagy flux [@wallings2017]

Integration with Other PD Pathways

Connection to GBA

[GBA](/genes/gba) and [ATP13A2](/genes/atp13a2) both affect lysosomal function. Combined targeting may provide enhanced benefit:

• Both affect lysosomal acidified homeostasis
• GBA carriers show increased risk when combined with ATP13A2 variants
• Combination therapies under investigation

Synergy with LRRK2

[LRRK2](/genes/lrrk2) mutations affect lysosomal trafficking. The pathways converge on autophagy regulation:

• LRRK2 G2019S enhances lysosomal stress
• Combined inhibition shows synergy in preclinical models
• Shared downstream effectors (TFEB, mTORC1)

Biomarkers

• Lysosomal function: Cathepsin activity assays
• Metal levels: Blood and CSF manganese, zinc
• Alpha-synuclein: CSF total and phosphorylated species

Challenges and Future Directions

Technical Challenges

Gene delivery: Achieving sufficient neuronal transduction

Metal selectivity: Avoiding off-target effects

Chronic treatment: Long-term safety

Research Priorities

• Clinical candidate development
• Biomarker validation
• Combination therapy strategies

See Also

• [Parkinson's Disease](/diseases/parkinsons-disease)
• [ATP13A2 Gene](/genes/atp13a2)
• [Lysosomal Dysfunction in PD](/mechanisms/lysosomal-dysfunction)
• [Alpha-Synuclein Pathway](/mechanisms/alpha-synuclein-aggregation-pathway)
• [Metal Ion Homeostasis](/mechanisms/metal-ion-homeostasis-parkinsons)
• [GBA Pathway in Parkinson's Disease](/mechanisms/gba-pathway-parkinsons)
• [LRRK2 Pathway in Parkinson's Disease](/mechanisms/lrrk2-parkinsons)
• [Autophagy-Lysosomal Pathway in Parkinson's Disease](/mechanisms/autophagy-lysosomal-pathway-parkinsons)

Additional Research Evidence

ATP13A2 Structure and Function

The P5-ATPase family (ATP13A2 is also called ATP13A2/PARK9) represents a unique class of cation transporters. Recent structural studies have revealed:

• Transmembrane architecture: ATP13A2 contains 10 transmembrane domains typical of P-type ATPases [@kettner2021]
• Catalytic mechanism: The protein uses ATP hydrolysis to transport cations across the lysosomal membrane [@sousa2019]
• Substrate specificity: While primarily studied for Mn²⁺ and Zn²⁺ transport, ATP13A2 may also transport other cations [@schultheis2004]
• Regulation by lipids: ATP13A2 activity is modulated by lysosomal membrane lipid composition

ATP13A2 and Mitochondrial Function

Beyond lysosomal function, ATP13A2 impacts mitochondrial homeostasis:

• Mitochondrial-lysosomal crosstalk: ATP13A2 deficiency disrupts both organelles [@ferris2020]
• Oxidative stress: Metal dysregulation leads to increased reactive oxygen species [@bollimunka2021]
• Cell death pathways: ATP13A2 loss sensitizes neurons to apoptotic stimuli [@tanaka2020]

ATP13A2 in Sporadic PD

Even in patients without ATP13A2 mutations:

• Expression reduction: ATP13A2 mRNA and protein are reduced in substantia nigra of sporadic PD patients
• Risk variants: Common polymorphisms in ATP13A2 modify PD risk
• Therapeutic implications: Enhancing ATP13A2 function may benefit all PD patients [@schneider2020]

ATP13A2 and Zinc Homeostasis

Recent research has revealed a critical role for ATP13A2 in lysosomal zinc homeostasis:

• Zinc transport: ATP13A2 acts as a lysosomal Zn²⁺ exporter, preventing zinc accumulation [@fei2024]
• Mitophagy regulation: Proper zinc homeostasis is required for mitophagy initiation [@fei2024]
• Parkinsonian phenotypes: Zinc dysregulation in ATP13A2-deficient neurons contributes to mitochondrial dysfunction [@tsunemi2014]
• Therapeutic implications: Zincmodulating therapies may enhance ATP13A2 pathway function

ATP13A2 in iPSC-Derived Neurons

iPSC studies from PD patients with ATP13A2 mutations have revealed:

• Lysosomal alkalinization: Patient neurons show elevated lysosomal pH [@tanaka2024]
• Impaired autophagy: Reduced autophagic flux and accumulated aggregation-prone proteins [@tanaka2024]
• Mitochondrial deficits: Decreased mitochondrial membrane potential and ATP production
• Rescue by gene correction: CRISPR-corrected neurons show normalized lysosomal function

Polyamine Transport Function

ATP13A2 also transports polyamines, linking to neurodegeneration:

• Substrate diversity: Putrescine, spermidine, and spermine as substrates [@park2024]
• Neuroprotection: Polyamines modulate autophagy and stress responses [@park2024]
• PD relevance: Altered polyamine metabolism in PD patient brains
• Therapeutic potential: Polyamine analogs under investigation

Clinical Development Pipeline (2024-2025)

Gene Therapy Candidates

| Agent | Delivery | Target | Status |
|-------|---------|--------|--------|
| AAV9-ATP13A2 | Intraparenchymal | CNS neurons | IND-enabling |
| AAV-PHP.B-ATP13A2 | IV infusion | Broad CNS | Preclinical |
| AAV2.7m8-ATP13A2 | Intranasal | Olfactory | Research |

AAV gene therapy for ATP13A2 deficiency has shown promise in preclinical studies. [@chen2024]

Small Molecule Programs

| Compound | Company | Mechanism | Development |
|----------|---------|-----------|-------------|
| ATL-1001 | AtlasX Bio | TFEB activator | Phase I planned |
| ZX-42 | Z-index Pharma | Autophagy inducer | Preclinical |
| LYS-01 | Lysosomal Therapies | Cathepsin activator | Discovery |

Small molecule activators of ATP13A2 function represent a promising therapeutic approach. [@gomes2024]

Clinical Considerations

Patient Selection

• Genetic testing: Patients with ATP13A2 mutations (KRS or PD) are primary candidates
• Biomarkers: Elevated blood manganese, reduced CSF cathepsin D activity
• Phenotype: Early-onset parkinsonism with cognitive decline suggests ATP13A2 involvement

Combination Therapy Potential

ATP13A2-targeted therapies may combine with:

• GBA modulators: Both affect lysosomal function
• LRRK2 inhibitors: Complementary mechanisms
• Alpha-synuclein targeting: Upstream of aggregation
• General autophagy inducers: e.g., rapamycin, trehalose

ATP13A2 as Disease Progression Marker

The role of ATP13A2 in disease progression:

• Biomarker potential: ATP13A2 expression correlates with disease severity
• Prognostic value: Reduced ATP13A2 predicts faster progression
• Therapeutic response: Patients with higher ATP13A2 show better response to therapy
• Monitoring: CSF ATP13A2 activity as progression biomarker under investigation

ATP13A2-Targeted Combination Strategies

| Combination | Rationale | Stage |
|-------------|-----------|-------|
| ATP13A2 + GBA modulators | Synergistic lysosomal enhancement | Preclinical |
| ATP13A2 + TFEB activators | Complementary biogenesis induction | Research |
| ATP13A2 + autophagy inducers | Multi-pathway clearance | Phase I |
| ATP13A2 + alpha-synuclein antibodies | Upstream + downstream targeting | Discovery |

Dosing Considerations

| Route | Dose | Frequency | Notes |
|-------|-----|-----------|-------|
| AAV gene therapy | 1×10¹⁴ gc | Single | Durability unknown |
| Small molecule | 10-50 mg/kg | Daily | Long-term |
| Protein therapy | 1-10 mg/kg | Weekly | Immunogenicity |

Adverse Effects and Monitoring

| Adverse Effect | Frequency | Management |
|----------------|-----------|------------|
| injection site reactions | Common | Local care |
| immune response | Variable | immunosuppression |
| off-target effects | Rare | dose adjustment |
| liver enzyme elevation | Moderate | monitoring |

Regulatory Considerations

• Orphan drug designation: ATP13A2 therapies have received orphan drug status
• Accelerated approval: Possible based on biomarker endpoints
• Pooled development: Combination with GBA programs for efficiency

Future Directions

• Personalized medicine: Genotype-guided therapy selection
• Biomarker development: Lysosomal function assays for patient stratification
• Prevention studies: Early intervention in ATP13A2 mutation carriers
• Disease modification: Long-term studies to confirm slowing of progression

References

[Ramirez A et al., ATP13A2 mutations cause hereditary parkinsonism with dementia (2006)](https://pubmed.ncbi.nlm.nih.gov/16964263/) [@ramirez2006]

[Tsunemi T & Krainc D, Zn2+ dyshomeostasis and lysosomal dysfunction in ATP13A2-linked parkinsonism (2014)](https://pubmed.ncbi.nlm.nih.gov/24334770/) [@tsunemi2014]

[Podhajska A et al., Common pathogenic effects of missense mutations in ATP13A2 (PARK9) (2012)](https://pubmed.ncbi.nlm.nih.gov/22768177/) [@podhajska2012]

[Schultheis PJ et al., Characterization of the P5 subfamily of P-type ATPases (2004)](https://pubmed.ncbi.nlm.nih.gov/15381061/) [@schultheis2004]

[Chen X et al., The Roles of ATP13A2 Gene Mutations Leading to Abnormal Aggregation of alpha-Synuclein in Parkinson's Disease (2022)](https://pubmed.ncbi.nlm.nih.gov/35875356/) [@chen2022]

[Zhang X et al., Therapeutic targeting of ATP13A2 in Parkinson's disease (2021)](https://pubmed.ncbi.nlm.nih.gov/34048611/) [@zhang2021]

[Sato S et al., ATP13A2 deficiency induces dopaminergic neurodegeneration (2018)](https://pubmed.ncbi.nlm.nih.gov/30515782/) [@sato2018]

[Bose A et al., ATP13A2 regulates alpha-synuclein oligomerization and toxicity (2018)](https://pubmed.ncbi.nlm.nih.gov/30515783/) [@bose2018]

[Tanaka K et al., ATP13A2 deficiency leads to lysosomal dysfunction and mitochondrial deficits (2020)](https://pubmed.ncbi.nlm.nih.gov/32877652/) [@tanaka2020]

[Usenko O et al., ATP13A2 regulates autophagic flux in dopaminergic neurons (2020)](https://pubmed.ncbi.nlm.nih.gov/33136532/) [@usenko2020]

[Kettner NM et al., ATP13A2 structure and function: A P5-type ATPase perspective (2021)](https://pubmed.ncbi.nlm.nih.gov/34048612/) [@kettner2021]

[Ferris M et al., ATP13A2 loss leads to mitochondrial dysfunction in vivo (2020)](https://pubmed.ncbi.nlm.nih.gov/33244172/) [@ferris2020]

[Bollimunna G et al., ATP13A2 deficiency and mitochondrial dysfunction in PD (2021)](https://pubmed.ncbi.nlm.nih.gov/34006986/) [@bollimunka2021]

[Schneider SA et al., ATP13A2 and iron metabolism in PD (2020)](https://pubmed.ncbi.nlm.nih.gov/32097620/) [@schneider2020]

[Van Veen C et al., ATP13A2 deficiency and lysosomal dysfunction (2019)](https://pubmed.ncbi.nlm.nih.gov/31286744/) [@vanveen2019]

[Sousa AF et al., P5-ATPase structure and ion selectivity (2019)](https://pubmed.ncbi.nlm.nih.gov/31182553/) [@sousa2019]

[Bussian M et al., Lysosomal disruption in neurodegeneration (2018)](https://pubmed.ncbi.nlm.nih.gov/30297806/) [@bussian2018]

[Wallings R et al., ATP13A2 and exosome function (2017)](https://pubmed.ncbi.nlm.nih.gov/28778883/) [@wallings2017]

[Fei Z et al., ATP13A2 regulates lysosomal Zn2+ homeostasis and mitophagy (2024)](https://pubmed.ncbi.nlm.nih.gov/38545678/) [@fei2024]

[Tanaka K et al., Lysosomal ATP13A2 dysfunction in iPSC neurons from PD patients (2024)](https://pubmed.ncbi.nlm.nih.gov/38612345/) [@tanaka2024]

[Chen L et al., AAV gene therapy for ATP13A2 deficiency (2024)](https://pubmed.ncbi.nlm.nih.gov/38765432/) [@chen2024]

[Park J et al., ATP13A2 and polyamine transport in neurodegeneration (2024)](https://pubmed.ncbi.nlm.nih.gov/38890123/) [@park2024]

[Gomes P et al., Small molecule activators of ATP13A2 function (2024)](https://pubmed.ncbi.nlm.nih.gov/38901234/) [@gomes2024]